Vor Biopharma Inc.

Vor Biopharma Inc.

VOR·NASDAQ

$14.32

+6.5%
HealthcareBiotechnology

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$98.15M
EPS-70.5000
P/E Ratio-0.20
Earnings Date08/11/2026

vor

Other Current Liabilities

Last Annual Value

15.33M

3-Year CAGR

46%

5-Year CAGR

29%

10-Year CAGR

17%

Vor Biopharma Inc.

Vor Biopharma Inc. Competitors Analysis of Other Current Liabilities

VOR · NASDAQ
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
15.33M
45.6%104.0%N/A 
10.76M
124.8%N/A8.6%
5.58M
20.1%N/A4.2%
CDXS logo
Codexis, Inc.
NASDAQ:CDXS
13.81M
7.1%4.4%30.8%
16.07M
-9.3%-6.1%-5.0%
16.84M
655.9%163.1%35.8%
5.80M
N/A7.1%N/A
87.10M
123.0%45.2%37.6%
OABI logo
OmniAb, Inc.
NASDAQ:OABI
7.33M
-2.0%8.3%N/A
9.89M
54.9%66.2%N/A
6.23M
43.4%28.2%4.7%
Vor Biopharma Inc.

Vor Biopharma Inc. Fair Value Envelope

VOR · NASDAQ

Our analysis suggests that VOR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $14.32, this represents a potential HIDDEN relative to our calculated worth for Vor Biopharma Inc..

Intrinsic Value
Current Price: $14.32